TYBR Health

TYBR Health is a private, pre-revenue medical device company focused on solving the pervasive problem of post-surgical adhesions that limit patient mobility despite technically successful surgeries. Its lead product, the B3 GEL™ System, is a flowable, blue-tinted hydrogel barrier that physically separates healing tissues during the critical recovery window to prevent restrictive scar formation. Founded in 2019 and based in Austin, Texas, the company has developed its technology through NIH-funded and university-collaborative research, generating preclinical data demonstrating improved range of motion and reduced adhesions without impairing tendon gliding. TYBR is now positioned to bring this integrated surgical solution to the substantial market of orthopedic and hand surgery procedures.

Flowable, extracellular matrix (ECM)-based bio-gel barrier with a blue colorant for precise surgical application. Designed to create a conforming, protective separation between healing tendons/ligaments and surrounding tissues to prevent adhesion formation.

The competitive landscape for anti-adhesion products includes existing absorbable solid sheets/films and off-label use of hyaluronic acid gels, but few are specifically designed and validated for tendon gliding spaces. TYBR's primary competition may come from other early-stage companies developing novel hydrogel barriers and from large orthopedic incumbents that could develop or acquire similar technologies.